Stimulation of Cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1180-1187

  Fox, Susan H ^a,c   Henry, Brian ^a,d   Hill, Michael ^b   Crossman, Alan ^b   Brotchie, Jonathan ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Williams House   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cannabinoid; Dyskinesia; MPTP; Nabilone; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; BENSERAZIDE PLUS LEVODOPA; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; GLUTAMIC ACID; LEVODOPA; NABILONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ACTIVITY; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; HYPOTHESIS; LONG TERM CARE; MALE; MARMOSET; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RATING SCALE; REVIEW; SCORING SYSTEM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; CALLITHRIX; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; LEVODOPA; MALE; MOTOR SKILLS; PARKINSONIAN DISORDERS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

EID: 0036868444     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10289     Document Type: Review

References (47)

1. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
2. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
3. Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease; phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
4. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995; 45:1855-1858.
5. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
6. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
7. Bezard E, Brotchie JM, Gross CE. 2001 Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: opportunities for novel treatments. Nat Neurosci Rev 2001;2:577-588.
8. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1-20.
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
10. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995;270:3726-3731.
11. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
12. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-583.
13. Mailleux P, Parmentier M, Vanderhaeghen JJ. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 1992; 143:200-204.
14. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988;36:189-261.
15. Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991;30:237-244.
16. Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996;308:161-164.
17. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996;22:382-385.
18. Sieradzan K, Fox SH, Hill M, Dick JPR, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
19. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001;85:468-471.
20. Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, Crossman AR. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990;5:49-54.
21. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992;115:809-824.
22. Crossman AR, A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
23. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65:59-70.
24. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
25. Ward A, Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985;30:127-144.
26. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
27. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999;14:744-753.
28. Brotchie JM, Fox SH. Quantitative assessment of dyskinesias in subhuman primates. Mov Disord 1999;14(Suppl. 1):S40-S47.
29. Vitek JL, Chockkan V, Zhang JY, Kaneoke Y, Evatt M, DeLong MR, Triche S, Mewes K, Hashimoto T, Bakay RA. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999;46:22-35.
30. Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999;46:732-738.
31. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease Neurology 1998;51(Suppl. 2):S30-S35.
32. Brotchie JM. Advances in understanding the neural mechanisms underlying L-dopa-induced dyskinesia. Adv Neurol 1999;80:71-85.
33. Hillard CJ, Auchampach JA. In vitro activation of brain protein kinase C by the cannabinoids. Biochim Biophys Acta 1994;1220:163-170.
34. Guestella PM, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel MC, Davisons N, Lester HA, Kanner BI. Clonong and expression of a rat brain GABA transporter. Science 1990;249:1303-1306.
35. Tersigni TJ, Rosenberg HC. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 1996;733:184-192.
36. Chan PKY, Yung W-H. Occlusion of the presynaptic action of cannbinoids in rat substantia nigra pars reticulata by cadmium. Neurosci Lett 1998;249:57-60.
37. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. The neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha, adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-650.
38. Pearce RKB, Banjerji T, Jackson M, Jenner P, Marsden CD. Cholinergic manipulation Of L-dopa-induced chorea and dystonia in the MPTP-treated common marmoset. Mov Disord 1996;11(Suppl.1): 200P.
39. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578.
40. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30:277-282.
41. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. A randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002;17:145-149.
42. Sañudo-Peña, MC, Walker JM. Role of the subthalamic nucleus on cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997;77:1635-1638.
43. Szabo B, Wallmichrath I, Mathonia P, Pfreundter C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 2000;97:89-97.
44. Romero J, De Miguel R, Ramosa JA, Fernandez-Ruiz JJ. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci 1998;62:351-363.
45. Miller AS, Walker JM. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 1996;304:29-35.
46. Fox SH, Hill MP, Peggs D, Crossman AR, Brotchie JM. The role of endocannabinoids in L-dopa-induced dyskinesia. Proc Soc Neurosci 1999;25:585.17.
47. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-dopa or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.